Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Lindsey E. Roeker et al.|Blood|2020Cited by 318
COVID-19 in patients with CLL: improved survival outcomes and update on management strategiesLindsey E. Roeker, Sigrid S. Skånland, Nicolás Martínez‐Calle et al.|Blood|2021Cited by 70
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S. Davids, Jennifer R. Brown, Christine E. Ryan et al.|Journal of Clinical Oncology|2024Cited by 40
Initial results of a multicenter phase 2 study of venetoclax in combination with R‐CHOP (VR‐CHOP) for patients with Richter SyndromeMatthew S. Davids, Philip A. Thompson, Kathleen A. Rogers et al.|Hematological Oncology|2023Cited by 23
Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk DiseaseChristine E. Ryan, Matthew S. Davids, Benjamin L. Lampson et al.|Blood|2022Cited by 23